ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting
(WorldNews Health)

SAN DIEGO--(BUSINESS WIRE)--May 18, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced it will present data from its Phase 2 CLARITY study, which evaluated the efficacy, safety, and tolerability of pimavanserin as an adjunctive treatment for major depressive disorder (MDD) at the 2019 American Psychiatric Association Annual Meeting in San Francisco, May 18 - 22, 2019. Poster Presentation Poster: #P8-049 Date/Time: Tuesday, May 21, 2:00 p.m. - 4:00 p.m. Pacific Time Title: CLARITY: A Phase 2 Double-blind,...